MSC Therapy for Pediatric Acute GvHD: From FDA Approval to Next-Generation Approaches

The first FDA-approved MSC therapy (Ryoncil) ended a 20-year drought for cell-based products in the US. New real-world data from 139 children and next-generation platforms are reshaping how clinicians treat steroid-refractory pediatric GvHD.